On May 23rd, 2023, Viva Biotech (Shanghai) Ltd. ("Viva Biotech") and DP Technology Co., Ltd. ("DP Technology") announced that they have entered into a strategic partnership to fully integrate advantageous resources and work closely together to advance RNA-targeted small molecule drug discovery based on AI4S, given the synergies and complementarities of their respective businesses and technologies.
Under the terms of the strategic collaboration agreement, DP Technology will provide its existing Hermite® Drug Computing Design Platform in the AI4S field to strengthen structure-based drug design, particularly in RNA-targeted small molecule drug discovery, and jointly build a brand-new targeted compound library with Viva Biotech. Meanwhile, based on Viva’s technological advantages in structural biology, affinity-based drug screening, lead compound validation, and other early-stage drug discovery fields, and combined with DP Technology's algorithms of Uni-EM, Uni-FEP, Uni-Mol, the two parties will jointly build an integrated platform for RNA-targeted small molecule drug discovery based on AI4S, which achieved both dry and wet approaches to drug discovery, as well as the evaluation of compound drug-likeness, aims to further enhance the efficiency of RNA-targeted small molecule drug screening and discovery.
Dr. Derek Ren, Executive Director and President of Viva Biotech, said, "We are delighted to enter into the strategic collaboration with DP Technology. There are significant synergies between our technology platforms. As a pioneer of the ‘AI for Science’ scientific research paradigm, DP Technology has all the advantages in the AI4S field. Viva possesses a strong capability in early-stage drug discovery and technological barriers. With joint efforts, we expect to improve the efficiency and success rate of RNA small molecule drug discovery and bring more innovative achievements and breakthroughs."
Mr. Weijie Sun, the founder and CEO of DP Technology, also commented, "We very much look forward to working closely with Viva, to create new opportunities for RNA-targeted small molecule drug discovery with our technological advantages in respective fields . Together, we will advance the development of drug discovery technology and contribute to human health."
The launch of this collaboration will lay a solid foundation for further in-depth cooperation between Viva and DP Technology. The two parties will work together to provide great support to innovative drug discovery for global pharmaceutical companies, jointly advance the development of AI-based RNA-targeted small molecule drug discovery and bring good news to patients around the world.
About DP Technology Co., Ltd.
DP Technology is a global pioneer of "AI for Science”,a new research paradigm aspiring to solve significant scientific challenges by fusing artificial intelligence,molecular dynamics,and multi-scale modeling. DP Technology is creating the next-generation design and simulation platform for global researchers in the field of life science,energy science,material science,information science,and other related engineering domains.
Stemming from the foundation of "AI for Science”,DP Technology has developed Bohrium scientific computing platform,Hermite drug discovery platform,proprietary compute engine RiDYMO and various industry-specific solutions. DP’s suite of solutions aims at bridging the gap between dry and wet lab by “guiding experiment design with computation” and “fusing experimental result into computation” iteratively. Innovation-driven companies and institutions could benefit greatly from DP’s powerful tools and accumulate lasting competitive edge by embracing the new paradigm of “AI for Science”.
DP Technology is a national high-tech and SRDI（Specialized,Refined,Differential,Innovative）small and medium-sized enterprise,headquartered in Beijing,and has R&D centers in Shanghai and Shenzhen.With academicians of the Chinese Academy of Sciences in the lead,the scientific research and technology team brings together nearly 100 outstanding young scientists and engineers in mathematics,physics,chemistry,biology,materials,computer and other fields. The company's doctor and post-doctor account for more than 35%.The core members have won the “2020 Gordon Bell Award”,which is the highest award in the field of global high performance computing. Their related work has been selected as “the top ten scientific and technological progress in China” and “the top ten technological breakthroughs in the field of global AI in 2020”.
Copyright © Viva Biotech All Rights Reserved. 沪ICP备19036061号
- About Us
-
CRO Services
BackCRO ServicesDiscovery Biology Services
- CDMO Services
- EFS Business
- News
- Careers
- Investor Relations
- Contact Us